Ownership Summary
Recent 13F filings as of December 2025 show that 9 institutional investors hold a position in bioAffinity Technologies, Inc. (NASDAQ:BIAF).
- bioAffinity Technologies saw its institutional ownership percentage fell to 11.1% in December 2025 from 42.9% in September 2025.
- In percentage terms, this reflects as a holdings change of 1439.50% quarter on quarter, and a decrease of 47.06% year over year.
- Among the 9 institutional holders of bioAffinity Technologies, 6 added to their stakes while 1 trimmed their positions and 2 held steady.
- The aggregate institutional position in bioAffinity Technologies now stands at 78.42K shares as of December 2025, after investors increased their holdings (up by 73.33K shares quarter on quarter which is up 60.57K shares year over year).
- The top institutional stake in bioAffinity Technologies as of December 31, 2025 belongs to GEODE CAPITAL MANAGEMENT, LLC, which owns 30.42K shares, or 4.32% of the company.
- Among the most significant buyers of bioAffinity Technologies during December 2025 were GEODE CAPITAL MANAGEMENT, LLC (30.42K), NORTHERN TRUST CORP (12.72K), CITADEL ADVISORS LLC (11.63K), TWO SIGMA SECURITIES, LLC (11.12K), CITIGROUP INC (7.67K).
- Leading sellers of bioAffinity Technologies stock in December 2025 included BANK OF AMERICA CORP /DE/ (1.65K).
- The top 9 institutional holders of bioAffinity Technologies for the quarter ending December 2025 included GEODE CAPITAL MANAGEMENT, LLC (30.42K), NORTHERN TRUST CORP (12.72K), CITADEL ADVISORS LLC (11.63K), TWO SIGMA SECURITIES, LLC (11.12K), CITIGROUP INC (7.74K), Tower Research Capital LLC (TRC) (3.90K), IFP Advisors, Inc (833), BANK OF AMERICA CORP /DE/ (38), MORGAN STANLEY (3).